100亿美元!诺和诺德更新收购Metsera报价;辉瑞终止开发11个项目

氨基观察
Nov 06, 2025

减重巨头争抢核心资产。11月4日,诺和诺德提交了一份更新的、主动提出的收购Metsera的提案。该提案对Metsera的估值高达每股86.20美元,总计约100亿美元,比截至2025年9月19日(辉瑞交易宣布前的最后一个交易日)的Metsera收盘价溢价约159%。辉瑞在布局新管线的同时,也在及时止损。11月4日,辉瑞在发布2025Q3业绩,披露了11个终止开发的项目,涉及两款mRNA疫苗、一款...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10